Illumina, Inc. (ILMN)

Gene sequencing instruments and reagents maker. Read October 19, 2026 from the annual report for the period ending December 28, 2025, filed February 12, 2026. Ranked 50 of the 104 Healthcare companies read so far, by the share within reach now.

A genomics company whose filing counts 8,650 employees by region with 1,430 contingent workers apart, and nothing by kind of work, so instruments lead by description with consumables and software beside them.

The figures on this page come from the company's own annual report and from BLS staffing patterns for its industries, never from a roster. They are estimates with a stated method. Nothing here says what the company will do: within reach is not a forecast of jobs lost or of savings.

What follows from the reading

Share of working time within reach of AI, on the long-run pace at four in five: 19% now, 39% at the end of 2027, 49% at the end of 2028, 53% at the end of 2030. By the patterns, the work is about 53% desk work, 17% people work and 30% body work. These are the site's industry estimates weighted by the shares below: estimates with a stated method and range, not a forecast of what the company will do. By the same patterns, at the end of 2028 about 47% of the working time stays with people (conversation, in-person and hands-on work), 43% becomes checking a model's work and 5% could be handed over with lighter checks, from the industries' own figures, not the company's roles.

Headcount

8,650 employees as of December 28, 2025 (sum of stated parts). Not stated as the United States: approximately 4,740 employees (55%) in the Americas, 1,280 in Europe, 2,350 in Africa, the Middle East and Asia, and 290 in Greater China.

The filing: “As of December 28, 2025, our global workforce was comprised of approximately 8,600 full time employees, 50 part time employees, and 1,430 contingent workers.”

The workforce as industry patterns

What the filing says about the workforce: Approximately 8,600 full-time and 50 part-time employees as of December 28, 2025 (8,970 a year earlier), plus 1,430 contingent workers not counted: about 4,740 in the Americas, 1,280 in Europe, 2,350 in Africa, the Middle East and Asia, 290 in Greater China; global voluntary turnover 8%.

Companies read with the same leading pattern

Other companies whose largest staffing pattern is also Navigational, Measuring, Electromedical, and Control Instruments Manufacturing, largest first, each read from its own annual report. Within reach now and at the end of 2028, long-run pace, four in five.

• Medtronic plc (MDT, 95,000 employees)19% now, 43% by 2028
• Emerson Electric Co. (EMR, 71,000 employees)20% now, 48% by 2028
• Danaher Corporation (DHR, 60,000 employees)19% now, 45% by 2028
• GE HealthCare Technologies Inc. (GEHC, 54,000 employees)19% now, 50% by 2028
• L3Harris Technologies, Inc. (LHX, 45,000 employees)18% now, 48% by 2028
• Rockwell Automation, Inc. (ROK, 26,000 employees)21% now, 57% by 2028
• Garmin Ltd. (GRMN, 23,000 employees)19% now, 49% by 2028
• AMETEK, Inc. (AME, 22,500 employees)18% now, 42% by 2028

What the filing says about AI

16 sentences in the filing name AI. The filing describes Emedgene, an AI-driven genomic interpretation software platform, names competitors' greater artificial intelligence capabilities, and says uncertainties in developing and using AI in its business and products may harm its business and reputation.

• “Emedgene is an AI-driven genomic interpretation software platform designed to support clinical research and translational research workflows, including rare disease and inherited condition research, by enabling users to curate, prioritize, and analyze genomic variants using a continuously evolving knowledge graph.”
• “Some of our competitors have, or will have, substantially greater financial, technical, research, artificial intelligence capabilities, and other resources than we do, along with larger, more established marketing, sales, distribution, and service organizations.”
• “Reductions in the prices at which our tests are reimbursed could have a negative impact on our results of operations. 18 Uncertainties with respect to the development, deployment, and use of artificial intelligence in our business and products may result in harm to our business and reputation.”
• “We have incorporated, and expect to continue to incorporate, artificial intelligence (AI) into our business activities and our product and service offerings.”
• “As with many innovations, AI presents risks and challenges that could adversely impact our business.”

Its annual reports, year by year

Sentences naming AI in each annual report, counted by one rule, beside the median report in the Index that year. Each count links its filing. Every company, by year and sector

• Fiscal 20211median 0
• Fiscal 20221median 0
• Fiscal 20234median 1
• Fiscal 202414median 4
• Fiscal 202516median 10

Headcount by filing year

As reported in each year's annual report, with the filing. A year marked not read had no figure the reading could take from the report's text.

Limits of this reading

• The collector's 4,740 is the Americas count; the filing's total is 8,600 full-time and 50 part-time employees, summed (rule 2).
• 1,430 contingent workers are not employees and are not counted (rule 8).
• The U.S. share is not stated: 55% in the Americas.
• No count by kind of work: the split among instruments, consumables and software is by description (c).

Source: the company's annual report on EDGAR, accession 0001110803-26-000024, the filing. Read by Claude Fable 5.1 under rubric version 1, by the method. A company can write to info@stratussc.com to have its reading checked against its filing.